Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06756191 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Antifungal Drugs in Pulmonary Mucormycosis

StatusNot Yet Recruiting
PhasePhase 4
SponsorBin Cao
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 1, 2025 (before its estimated July 10, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Bin Cao
4 trials monitored
See all monitored trials
Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of 5mg/kg/day combined with isavuconazole versus using AmBisome for the management of pulmonary mucormycosis
Trial Details
NCT Number NCT06756191
Lead Sponsor Bin Cao
Conditions
(from sponsor)		 Pulmonary Mucormycosis
Enrollment 312 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov